Semi-Annual Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7339370

Concept 2024-01-01 to
2024-03-31
2023-01-01 to
2023-03-31
Semi-annual consolidated statement of income
Statement of income
Net sales
JPY
35,000,000 JPY
Cost of sales
JPY
32,433,000 JPY
Gross profit (loss)
JPY
2,566,000 JPY
Ordinary profit (loss)
-363,292,000 JPY
-323,092,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
378,872,000 JPY
328,145,000 JPY
Extraordinary income
JPY
136,000 JPY
Operating profit (loss)
-378,872,000 JPY
-325,578,000 JPY
Profit (loss) before income taxes
-363,292,000 JPY
-322,955,000 JPY
Non-operating income
Interest income
518,000 JPY
149,000 JPY
Non-operating income
19,187,000 JPY
3,341,000 JPY
Income taxes - current
940,000 JPY
736,000 JPY
Non-operating expenses
Interest expenses
1,140,000 JPY
855,000 JPY
Non-operating expenses
3,607,000 JPY
855,000 JPY
Income taxes
940,000 JPY
736,000 JPY
Extraordinary income
Gain on sale of non-current assets
JPY
136,000 JPY
Profit (loss)
-364,233,000 JPY
-323,691,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.